BioVie Inc.
from OTCQB Podcast Hosted by OTC Markets Group
100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of OTCQB Podcast?
This episode is 4 minutes long.
When was this OTCQB Podcast episode published?
This episode was published on August 29, 2017.
Can I download this OTCQB Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.